Literature DB >> 31556809

Cytokine-chemokine and cognitive profile of multiple sclerosis patients with predominant optic nerve and spinal cord involvement.

Melis Şen1, Ece Akbayır1, Özlem Mercan2, Erdil Arsoy2, Mehmet Gencer2, Vuslat Yılmaz1, Cem İsmail Küçükali1, Erdem Tüzün1, Recai Türkoğlu2.   

Abstract

Context/Objective: Clinical disease activity in multiple sclerosis (MS) may manifest as predominant involvement of optic nerves and spinal cord, as exemplified by opticospinal multiple sclerosis (OSMS) often encountered in Asian countries. Our aim was to compare the clinical features, neuropsychological profile and cytokine/chemokine levels of patients with conventional MS (CMS) and MS presenting predominantly with spinal cord and optic nerve attacks (MS-SCON).Design: Cross-sectional study.Setting: MS Outpatient Clinic.Participants: Fourteen MS-SCON patients, 20 CMS patients without myelitis and optic neuritis attacks and 21 healthy individuals.Outcome measures: IL-8, IL-10, IFN-γ, IL-17 and TNF-α levels were measured by multiplex assay and CXCL2 and CXCL5 levels were measured by ELISA. A panel of neuropsychological tests, Beck depression inventory, 9-hole peg and timed 25-foot walk tests were employed.
Results: CMS and MS-SCON patients showed similar clinical features. Both CMS and MS-SCON patients displayed reduced IL-8 and CXCL2 and increased TNF-α levels, while IL-10 and CXCL5 levels were identical among all groups.
Conclusion: Neuropsychological and motor function test performances of CMS and MS-SCON patients were highly comparable. CMS and MS-SCON present with similar clinical, neuropsychological and immunological features. Therefore, optic nerve and spinal cord-dominant form of MS does not necessarily establish a distinct entity in our region. Cognitive networks of the central nervous system may be damaged during the disease course of MS, despite the absence of cerebral or cerebellar clinical attacks.

Entities:  

Keywords:  Cognitive; Cytokine; Multiple sclerosis; Optic nerve; Spinal cord

Mesh:

Substances:

Year:  2019        PMID: 31556809      PMCID: PMC8081324          DOI: 10.1080/10790268.2019.1666238

Source DB:  PubMed          Journal:  J Spinal Cord Med        ISSN: 1079-0268            Impact factor:   1.985


  21 in total

1.  Benign multiple sclerosis: physical and cognitive impairment follow distinct evolutions.

Authors:  A Gajofatto; M Turatti; M R Bianchi; S Forlivesi; F Gobbin; A Azzarà; S Monaco; M D Benedetti
Journal:  Acta Neurol Scand       Date:  2015-05-26       Impact factor: 3.209

2.  Antibodies to myelin oligodendrocyte glycoprotein are uncommon in Japanese opticospinal multiple sclerosis.

Authors:  Sudarshini Ramanathan; Shinya Sato; Takuya Matsushita; Katsuhisa Masaki; Ryo Yamasaki; Russell C Dale; Jun-Ichi Kira; Fabienne Brilot
Journal:  Mult Scler       Date:  2015-05-26       Impact factor: 6.312

Review 3.  Neuronal injury in chronic CNS inflammation.

Authors:  Eva Zindler; Frauke Zipp
Journal:  Best Pract Res Clin Anaesthesiol       Date:  2010-11-29

4.  Influenza infection triggers disease in a genetic model of experimental autoimmune encephalomyelitis.

Authors:  Stephen Blackmore; Jessica Hernandez; Michal Juda; Emily Ryder; Gregory G Freund; Rodney W Johnson; Andrew J Steelman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-10       Impact factor: 11.205

5.  CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-β.

Authors:  J Jablonska; C-F Wu; L Andzinski; S Leschner; S Weiss
Journal:  Int J Cancer       Date:  2013-10-31       Impact factor: 7.396

6.  The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice.

Authors:  J B Boringa; R H Lazeron; I E Reuling; H J Adèr; L Pfennings; J Lindeboom; L M de Sonneville; N F Kalkers; C H Polman
Journal:  Mult Scler       Date:  2001-08       Impact factor: 6.312

7.  Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-I-associated myelopathy/tropical spastic paraparesis and hyperIgEaemic myelitis.

Authors:  H Ochi; X M Wu; M Osoegawa; I Horiuchi; M Minohara; H Murai; Y Ohyagi; H Furuya; J Kira
Journal:  J Neuroimmunol       Date:  2001-10-01       Impact factor: 3.478

8.  Increased CXCL8 (IL-8) expression in Multiple Sclerosis.

Authors:  Brett T Lund; Nazely Ashikian; Huy Q Ta; Yervand Chakryan; Krikor Manoukian; Susan Groshen; Wendy Gilmore; Gurtej S Cheema; William Stohl; Margaret E Burnett; David Ko; Norman J Kachuck; Leslie P Weiner
Journal:  J Neuroimmunol       Date:  2004-10       Impact factor: 3.478

9.  Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.

Authors:  M Krakauer; P Sorensen; M Khademi; T Olsson; F Sellebjerg
Journal:  Mult Scler       Date:  2008-04-18       Impact factor: 6.312

10.  The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease.

Authors:  Thaddeus Carlson; Mark Kroenke; Praveen Rao; Thomas E Lane; Benjamin Segal
Journal:  J Exp Med       Date:  2008-03-17       Impact factor: 14.307

View more
  1 in total

Review 1.  An evaluation of the recognised systemic inflammatory biomarkers of chronic sub-optimal inflammation provides evidence for inflammageing (IFA) during multiple sclerosis (MS).

Authors:  Christopher Bolton
Journal:  Immun Ageing       Date:  2021-04-14       Impact factor: 6.400

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.